Medindia

X

OmegaGenesis Announces Angiogenesis Application Collaboration

Monday, December 15, 2008 General News J E 4
Advertisement
Advances Research and Product Development of Nano-Materials for Angiogenesis Applications



GILROY, Calif. and ROCHESTER, Minn., Dec. 15 /PRNewswire/ -- OmegaGenesis announced today that they have entered into a collaboration with Mayo Clinic for the discovery and validation of nano-materials used for Angiogenesis applications.



Angiogenesis plays an important role in a wide variety of medical applications ranging from tissue reactivation and healing of common wounds to controlling the growth and spread of cancer and malignancies. In cancer and malignancies, new blood vessels feed the cancer cells with oxygen and nutrients, allowing these cells to grow, invade nearby tissue, spread to other parts of the body, and form new colonies of cancer cells.



At Mayo Clinic, researchers have produced one of the rare earth materials in nano size and established non-toxicity of the material for human applications. Additionally they have shown the material induces endothelial cell growth and produces new blood vessels. Considering the current limitation of therapy to create new functional blood vessels in ischemic diseases, this finding has significant potential for clinical application.



OmegaGenesis is developing applications based on these unique characteristics of nano materials for proactive maintenance of the human body. "Our goal is to supplement natural human body management and re-enable where some natural processes have stopped or diminished. These diminished capabilities lead to dysfunction of human body. Our approach provides for early and pre-disease intervention in most cases," said Mr. Raza, CEO of OmegaGenesis.



"Our collaboration with Mayo Clinic is an example of a strategically important long-term relationship. As a result of this research and product development collaboration, fundamental research conducted by Mayo Clinic is used by OmegaGenesis in the product development process and marketplace applications," said Oostur Raza.



It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.



OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test Angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.



In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.



About OmegaGenesis



OmegaGenesis, Inc. is a venture funded bio-technology company based in Gilroy, California and Rochester, Minnesota. OmegaGenesis was founded in 2008 to bring Mayo Clinic core research and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical applications ranging from cancer and malignancies treatments to common wound healing and tissue reactivation.



The Company was founded to discover and produce suitable nano-materials to manage human body functions at a nano scale -- the cell and sub-cell level -- accelerating cellular-based biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at sub-cell level in a non-intrusive manner instead of treating the disease at the organ or tissue level.



Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with strategic academic and corporate research partners as well as international partners. For additional information, please visit OmegaGenesis's corporate Website at www.omegagenesis.com



Media Contact: Heidi Chokeir, Ph.D. Russo Partners (619) 814-3512 OmegaGenesis Contact: Don Morrison 408-483-8258

SOURCE OmegaGenesis
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
VIDEO from Medialink and ACEP: Nation's Failure to...
S
OmegaGenesis Unveils Novel Nanotechnology Platform...